0000000001133228

AUTHOR

Mistretta O.

showing 1 related works from this author

NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri eve…

2021

OBJECTIVE: The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects. Chemotherapy-induced nausea and vomiting (CINV) are amongst the most troublesome side effects that impair patients’ adherence to treatments and their quality of life (QoL). NEPA (Akynzeo®), is an oral fixed-dose combination of netupitant [a neurokinin-1 receptor antagonist (NK1RA), 300 mg] and palonosetron [(5-hydroxytryptamine (serotonin or 5HT) type3 receptor antagonist (5HT3RA), 0.5 mg] which has been shown to be effective in preventing CINV. PATIENTS AND METHODS: This prospective study started before…

MalePyridinesVomitingCINVLeucovorinCOVID-19NauseaMiddle AgedIrinotecanColorectal cancerBevacizumabOxaliplatinPalonosetronNetupitantAntineoplastic Combined Chemotherapy ProtocolsAntiemeticsHumansEmetogenic chemotherapyFemaleFluorouracilProspective StudiesColorectal NeoplasmsPandemicsAdvanced pancreatic cancerAgedEuropean review for medical and pharmacological sciences
researchProduct